Elrig

MARCH 25, 2025

Prof Rory Johnson is an Associate Professor at University College Dublin, where his research focusses on uncovering the roles of long noncoding RNAs (lncRNAs) in human health and disease using an interdisciplinary combination of bioinformatic and experimental methods.

RNA 59

RNA Bioinformatics Science Pharmacokinetics 59

Practical Cheminformatics

JANUARY 8, 2024

A 2004 paper by Vigers and Rizzi proposed a similar strategy for docking studies. To address this challenge, they developed a new metric, Delta Score, which uses a panel of unrelated proteins to correct docking scores and identify “selective” molecules. It should be noted that this isn’t a new idea. What’s old is new again.

Drugs 136

Drugs Small Molecule Bioinformatics Packaging 136

Drug Target Review

DECEMBER 28, 2023

Recent advances in bioinformatics show clonal neoantigens are the best targets for immunotherapy, as I will elucidate below. Using powerful bioinformatics technology developed and validated with sequence data from the TRACERx study, researchers are able to identify clonal neoantigens from a patient’s unique tumour profile.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

Codon

AUGUST 10, 2023

PNAS (2004). Link Synthetic Genome Recoding: New genetic codes for new features , by Kuo J. Current Genetics (2017). Link An expanded genetic code with a functional quadruplet codon , by Anderson J.C. Link Sense codon reassignment enables viral resistance and encoded polymer synthesis , by Robertson W.E. Science (2021).

DNA 98

DNA Cell Biology Molecular Biology Engineering 98

Codon

AUGUST 10, 2023

PNAS (2004). Link Synthetic Genome Recoding: New genetic codes for new features , by Kuo J. Current Genetics (2017). Link An expanded genetic code with a functional quadruplet codon , by Anderson J.C. Link Sense codon reassignment enables viral resistance and encoded polymer synthesis , by Robertson W.E. Science (2021).

DNA 52

DNA Cell Biology Engineering Molecular Biology 52

Drug Target Review

APRIL 28, 2025

This bioinformatics-driven system allows the company to identify highly specific, cell-type-selective regulatory elements from the human genome. In 2004 he moved into the Biotech sector, spending five years running Gene Therapy R&D activities for Regulon Inc, joining the board in 2006.

Therapies 59

Therapies Regulations Bioinformatics Clinical Development 59